Study Evaluating the Clinical Benefit of SEROQUEL XR in Subjects With Schizophrenia

NCT ID: NCT00640601

Last Updated: 2012-06-25

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 331 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2008-03-31
• Study Completion Date: 2010-07-31

Brief Summary

A Multicentre, Open-label, Prospective Long-term Study Evaluating the Clinical Benefit and Effectiveness of SEROQUEL XR® (Quetiapine Fumarate Extended-Release Tablets) in Subjects with Schizophrenia.

Conditions

Schizophrenia

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Interventions

Quetiapine Fumarate Extended- Release

Open-label seroquel XR tablets: On Day 1 Patients received 300 mg, on Day 2 600 mg, on Day 3 600-800 mg and between Day 4-168 400-800 mg Seroquel XR, according to clinical judgement of investigator. Dose changes were in 200 mg fixed doses. Investigational product (IP) was supplied in open label wallet blister cards and subjects were instructed to take the IP once daily in the evening.

Intervention Type: DRUG

Other Intervention Names

Seroquel XR®

Eligibility Criteria

Inclusion Criteria

• Provision of written informed consent before initiation of any study related procedures.
• Male and female subjects aged 18 to 65 years, inclusive.
• Documented clinical diagnosis meeting the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) criteria for any of the following: Schizophrenia DSM-IV, catatonic 295.20, disorganised 295.10, paranoid 295.30 and undifferentiated 295.90.
• Outpatient status.
• Subjects who in their own and/or in the Principal Investigator's opinion, consider their ongoing antipsychotic treatment inadequate because of insufficient efficacy, poor tolerance, and/or non acceptability of their actual dosage regimen (eg. b.i.d, t.i.d, etc).
• Monotherapy with current antipsychotic for at least 7 days prior to initiating treatment (ie, cannot be on more than one antipsychotic during the 7 day period prior to initiating study medication). Note: Subjects on a b.i.d regimen of seroquel IR for 7 days prior to enrolment are eligible to participate in the study.
• Female subjects of childbearing potential must have a negative serum pregnancy test at enrolment and be willing to use a reliable method of birth control, ie, barrier method, oral contraceptive, implant, dermal contraception, long-term injectable contraceptive, intrauterine device, or tubal ligation during the study.
• Capable to make treatment decisions, including being able to understand and comply with the requirements of the study, and judged as such by the Principal Investigator.
• Be able to read and write either English or French at a grade 7 proficiency level.

Exclusion Criteria

• First episode, drug naive schizophrenic subjects.
• Meeting the criteria for any other (than schizophrenia) DSM-IV Axis I diagnosis, concomitant organic mental disorder or mental retardation that in the opinion of the Principal Investigator may interfere with study conduct or interpretation.
• Substance/alcohol dependence or abuse at enrolment [except dependence in full remission (>3 months) and except caffeine and nicotine dependence] as defined by DSM-IV criteria. A urine drug screen will be performed. The Principal Investigator will evaluate the results along with medical history to determine if the patient meets DSM-IV criteria for substance abuse or dependence. However, a single urine toxicology screen for cocaine, heroin, methamphetamine or PCP will lead to exclusion.
• Subjects requiring treatment with another antipsychotic agent than investigational product during study.
• Subjects on seroquel IR once daily.
• Known lack of response to clozapine or treatment with clozapine within 4 weeks prior to enrolment.
• Known intolerance to seroquel IR.
• Subjects requiring treatment with disallowed medication following enrolment into the study.
• Subjects requiring treatment for epilepsy.
• Subjects who pose an imminent risk of suicide or danger to themselves or others, as judged by the Principal Investigator.
• Pregnancy or lactation.
• A thyroid-stimulating hormone (TSH) concentration more than 10% above the upper limit of the normal range of the laboratory used for sample analysis whether or not the patient is being treated for hypothyroidism or hyperthyroidism.
• Use of a depot or long-acting injectable antipsychotic drug within 1 dosing interval before Day 1 of treatment or during treatment.
• Use of drugs that induce or inhibit the hepatic metabolising cytochrome P450 3A4 enzymes within 14 days of the screening assessment period (Day -7 to 0). See Table 5.
• History of idiopathic or drug-induced agranulocytosis.
• A QTc interval longer than 450 msec (calculated using the Fridericia correction for heart rate) or ECG considered to show cardiac abnormality at enrolment as determined by a centrally located, experienced cardiologist, and confirmed by the Principal Investigator as clinically significant.
• Evidence of clinically relevant disease (eg, renal, hepatic, autonomic, endocrine, hematologic or ophthalmologic impairment, significant coronary artery disease, congestive heart failure, cerebrovascular disease, viral hepatitis B or C, acquired immunodeficiency syndrome [AIDS] or cancer) or a clinical finding that is unstable or that, in the opinion of the Principal Investigator, would be negatively affected by the investigational product or that would affect the investigational product.
• Laboratory test results outside the reference range considered by the Principal Investigator to be clinically significant and potentially interfere with the study outcome.
• A patient with Diabetes Mellitus (DM) fulfilling one of the following criteria:

• Unstable DM defined as HbA1c >8.5% at enrolment. Admitted to hospital for treatment of DM or DM related illness in past 12 weeks.
• Not under care of physician responsible for patient's DM care.
• Physician responsible for patient's DM care has not indicated that patient's DM is controlled.
• Physician responsible for patient's DM care has not approved patient's participation in the study.
• Has not been on the same dose of oral hypoglycemic drug(s) and/or diet for the four (4) weeks prior to randomisation. For thiazolidinediones (glitazones) this period should not be less than 8 weeks.
• Taking insulin whose daily dose on one occasion in the past 4 weeks has been more than 10% above or below their mean dose in the preceding 4 weeks.

Note: If a diabetic patient meets one of these criteria the patient is to be excluded even if the treating physician believes the patient is stable and can participate in the study.

• An absolute neutrophil count (ANC) of <1.5 x 109/L
• Inability to accommodate the visit schedule.
• History of non-compliance as judged by the Principal Investigator.
• Previous enrolment in the present study.
• Participation in another clinical study or compassionate use programme within 4 weeks of screening (Day -7 to 0).
• Involvement in the planning and conduct of the study (applies to both AstraZeneca staff or staff at the study site).

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

AstraZeneca

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Pierre Chue, MD

Role: PRINCIPAL_INVESTIGATOR

University of Alberta

Willie Early, MD

Role: STUDY_CHAIR

AstraZeneca

Locations

Research Site

Garran, Australian Capital Territory, Australia

Research Site

Newcastle, New South Wales, Australia

Research Site

Brisbane, Queensland, Australia

Research Site

Meadowbrook, Queensland, Australia

Research Site

Dandenong, Victoria, Australia

Research Site

Calgary, Alberta, Canada

Research Site

Claresholm, Alberta, Canada

Research Site

Red Deer, Alberta, Canada

Research Site

Vancouver, British Columbia, Canada

Research Site

Victoria, British Columbia, Canada

Research Site

Miramichi, New Brunswick, Canada

Research Site

St. John's, Newfoundland and Labrador, Canada

Research Site

Sydney, Nova Scotia, Canada

Research Site

Belleville, Ontario, Canada

Research Site

Brantford, Ontario, Canada

Research Site

Chatham, Ontario, Canada

Research Site

Cornwall, Ontario, Canada

Research Site

Greater Sudbury, Ontario, Canada

Research Site

London, Ontario, Canada

Research Site

Markham, Ontario, Canada

Research Site

Mississauga, Ontario, Canada

Research Site

Newmarket, Ontario, Canada

Research Site

Oakville, Ontario, Canada

Research Site

Orléans, Ontario, Canada

Research Site

Toronto, Ontario, Canada

Research Site

Windsor, Ontario, Canada

Research Site

Gatineau, Quebec, Canada

Research Site

Greenfield Park, Quebec, Canada

Research Site

Montreal, Quebec, Canada

Research Site

Québec, Quebec, Canada

Research Site

Rouyn-Noranda, Quebec, Canada

Research Site

Verdun, Quebec, Canada

Research Site

Prince Albert, Saskatchewan, Canada

Research Site

Saskatoon, Saskatchewan, Canada

Research Site

Hong Kong, , Hong Kong

Research Site

Seoul, Korea, South Korea

Countries

Australia; Canada; Hong Kong; South Korea

References

Chue P, Malla A, Bouchard RH, Lessard S, Ganesan S, Stip E, Johnson S, Chen E, Ahn YM, Kim YS, Robinson G, Schweikert C, Gendron A, Eriksson H; SPECTRUM XR Study Group. The long-term clinical benefit and effectiveness of switching to once-daily quetiapine extended release in patients with schizophrenia. Curr Med Res Opin. 2013 Mar;29(3):227-39. doi: 10.1185/03007995.2012.762903. Epub 2013 Jan 22.

Reference Type: DERIVED

PMID: 23281876 (View on PubMed)

Other Identifiers

D1443L00025

Identifier Type: -

Identifier Source: org_study_id